David J Yang Selected Research

David J Yang Research Topics

Disease

28	Neoplasms (Cancer) 02/2022 - 04/2002
9	Breast Neoplasms (Breast Cancer) 01/2013 - 05/2006
2	Endometriosis 01/2018 - 09/2007
2	Inflammation (Inflammations) 01/2018 - 08/2002
2	Mesothelioma 01/2013 - 01/2012
1	Infections 01/2018
1	Lymphoma (Lymphomas) 01/2013
1	Hypoxia (Hypoxemia) 01/2012
1	Carcinoma (Carcinomatosis) 12/2009
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2009
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 03/2009
1	Ovarian Neoplasms (Ovarian Cancer) 10/2008
1	Lung Neoplasms (Lung Cancer) 09/2005
1	Body Weight (Weight, Body) 05/2005
1	Squamous Cell Carcinoma of Head and Neck 10/2004
1	Infarction (Infarctions) 04/2003
1	Ischemic Stroke 04/2003
1	Neoplasm Metastasis (Metastasis) 01/2003
1	Mediastinitis 08/2002
1	Abscess 08/2002

Drug/Important Bio-Agent (IBA)

6	Chelating AgentsIBA 02/2022 - 01/2006
5	Tyrosine (L-Tyrosine)FDA Link 01/2013 - 08/2010
5	Pharmaceutical PreparationsIBA 01/2013 - 01/2006
4	RadiopharmaceuticalsIBA 01/2013 - 01/2006
4	Amino Acid Transport Systems (Amino Acid Transporter)IBA 01/2013 - 08/2010
4	Amino Acids FDA Link 01/2012 - 11/2006
3	Biological ProductsIBA 01/2013 - 01/2003
2	Estrogen ReceptorsIBA 01/2018 - 09/2007
2	Deoxyglucose (2 Deoxy D glucose)IBA 01/2013 - 10/2009
2	Oxygen (Dioxygen)IBA 01/2012 - 05/2006
2	Glucosamine (Dona)IBA 01/2012 - 01/2012
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 12/2009 - 03/2009
2	ErbB Receptors (EGF Receptor)IBA 12/2009 - 01/2003
2	ethylene dicysteineIBA 10/2009 - 10/2004
2	Cisplatin (Platino)FDA LinkGeneric 10/2008 - 05/2005
2	Aspartic Acid (Aspartate)FDA Link 10/2008 - 03/2008
2	IsotopesIBA 11/2007 - 01/2006
2	Cetuximab (Erbitux)FDA Link 10/2004 - 01/2003
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 02/2022
1	Tamoxifen FDA LinkGeneric 02/2022
1	Cell Surface ReceptorsIBA 01/2018
1	Glutamate Receptors (Glutamate Receptor)IBA 01/2018
1	LigandsIBA 01/2018
1	Aromatase InhibitorsIBA 01/2018
1	Estrogen Receptor Modulators (Antiestrogen)IBA 01/2018
1	Melphalan (Alkeran)FDA LinkGeneric 01/2013
1	ethyleneIBA 01/2013
1	Cysteine (L-Cysteine)FDA Link 01/2013
1	AntibodiesIBA 01/2013
1	TinIBA 01/2012
1	ChloridesIBA 01/2012
1	azomycinIBA 01/2012
1	technetium 99m O- (3- (1,4,8,11- tetraazabicyclohexadecane)propyl)- alpha- methyl tyrosineIBA 01/2011
1	Gefitinib (Iressa)FDA Link 12/2009
1	Imatinib Mesylate (Gleevec)FDA Link 03/2009
1	diammine dicarboxylic acid platinumIBA 10/2008
1	ChondroitinIBA 10/2008
1	PlatinumIBA 10/2008
1	Polysaccharides (Glycans)IBA 10/2008
1	Platinum Compounds (Compounds, Platinum)IBA 10/2008
1	Annexin A5IBA 09/2008
1	Paclitaxel (Taxol)FDA LinkGeneric 03/2008
1	GlycopeptidesIBA 03/2008
1	Glutamic Acid (Glutamate)FDA Link 03/2008
1	RheniumIBA 03/2008
1	Estrone FDA Link 09/2007
1	Diethylstilbestrol (Stilbestrol)FDA Link 03/2007
1	Lysine (L-Lysine)FDA Link 11/2006
1	Succimer (Dimercaptosuccinic Acid)FDA Link 11/2006
1	AcidsIBA 11/2006
1	gallium- 68- ethylenedicysteine- metronidazoleIBA 05/2006
1	GuanineIBA 09/2005
1	ThymidineIBA 09/2005
1	Thymidine KinaseIBA 09/2005
1	HydrogelsIBA 05/2005
1	Rhenium-188IBA 05/2005
1	Celecoxib (Celebrex)FDA Link 03/2004
1	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 03/2004
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 03/2004
1	technetium Tc 99m bicisate (Neurolite)FDA Link 04/2003
1	technetium 99m ethylenedicysteine-metronidazoleIBA 04/2003
1	Metronidazole (Metric)FDA LinkGeneric 04/2003
1	Glucose (Dextrose)FDA LinkGeneric 02/2003
1	Technetium (Technetium 99m)IBA 02/2003
1	(99m)Tc ethylenedicysteine-deoxyglucoseIBA 02/2003
1	Monoclonal AntibodiesIBA 01/2003
1	TurpentineIBA 08/2002
1	Liposomes (Liposome)IBA 08/2002
1	Indicators and Reagents (Reagents)IBA 04/2002
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2002
1	EndostatinsIBA 04/2002
1	Interleukin-8 (Interleukin 8)IBA 04/2002

Therapy/Procedure

9	Therapeutics 01/2014 - 04/2002
1	Aftercare (After-Treatment) 01/2013
1	Radioimmunotherapy 01/2013
1	Chemoradiotherapy 05/2005
1	Radiotherapy 01/2003